The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status
Journal of Oncological Sciences · 2019-12 · 5 (3) · 85-89
DOI: 10.1016/j.jons.2019.08.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncological Sciences, 2019-12. Verfasst von Abdullah Sakin und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Sakin, A., Sahin, S., atci, M. M., Demir, C., Yasar, N., Geredeli, C., & Cihan, S. (2019). The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status. Journal of Oncological Sciences, 5(3), 85-89. https://doi.org/10.1016/j.jons.2019.08.003
Vancouver
Sakin A, Sahin S, atci MM, Demir C, Yasar N, Geredeli C, et al. The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status. Journal of Oncological Sciences. 2019;5(3):85-89. doi:10.1016/j.jons.2019.08.003
BibTeX
@article{Sakin2019,
author = {Sakin, Abdullah and Sahin, Suleyman and atci, Muhammed Mustafa and Demir, Cumhur and Yasar, Nurgul and Geredeli, Caglayan and Cihan, Sener},
title = {The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status},
journal = {Journal of Oncological Sciences},
year = {2019},
volume = {5},
number = {3},
pages = {85--89},
doi = {10.1016/j.jons.2019.08.003}
}
EUVIMED